Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Friday morning. The firm issued a hold rating on the stock.

A number of other equities research analysts have also issued reports on EKSO. Lake Street Capital reduced their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. HC Wainwright reduced their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

Ekso Bionics Stock Down 0.8 %

Ekso Bionics stock opened at $0.57 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a 50 day moving average price of $0.84 and a 200 day moving average price of $1.02. Ekso Bionics has a fifty-two week low of $0.50 and a fifty-two week high of $3.13. The company has a market capitalization of $12.47 million, a PE ratio of -0.87 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter last year, the company earned ($0.24) earnings per share. Research analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.